These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24582759)

  • 21. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
    Arnal-Garcia C; García-Montero MR; Málaga I; Millán-Pascual J; Oliva-Nacarino P; Ramió-Torrentà L; Oreja-Guevara C
    Eur J Paediatr Neurol; 2013 Jan; 17(1):50-4. PubMed ID: 23021975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing-remitting multiple sclerosis.
    Sanoobar M; Eghtesadi S; Azimi A; Khalili M; Jazayeri S; Reza Gohari M
    Int J Neurosci; 2013 Nov; 123(11):776-82. PubMed ID: 23659338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
    J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"].
    Popova EV; Brylev LV; Davydovskaia MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):79-82. PubMed ID: 23528599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
    Saure C; Warnke C; Zohren F; Schroeder T; Bruns I; Cadeddu RP; Weigelt C; Fischer U; Kobbe G; Hartung HP; Adams O; Kieseier BC; Haas R
    Arch Neurol; 2011 Nov; 68(11):1428-31. PubMed ID: 22084125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis.
    Nakamura M; Itani K; Miyake K; Kunieda T; Kaneko S; Kusaka H
    Intern Med; 2017; 56(2):211-214. PubMed ID: 28090055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T; Vennegoor A; Wolbink GJ; Polman CH; Killestein J
    Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
    Pilz G; Harrer A; Oppermann K; Wipfler P; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    Mult Scler; 2012 Apr; 18(4):506-9. PubMed ID: 21965415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.
    Rossi S; Motta C; Studer V; Monteleone F; De Chiara V; Buttari F; Barbieri F; Bernardi G; Battistini L; Cutter G; Stüve O; Salvetti M; Centonze D
    Mult Scler; 2013 Jan; 19(1):59-68. PubMed ID: 22577119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Heisen M; Treur MJ; van der Hel WS; Frequin ST; Groot MT; Verheggen BG
    J Med Econ; 2012; 15(6):1149-58. PubMed ID: 22737996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study.
    Arru G; Leoni S; Pugliatti M; Mei A; Serra C; Delogu LG; Manetti R; Dolei A; Sotgiu S; Mameli G
    Mult Scler; 2014 Feb; 20(2):174-82. PubMed ID: 23877972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
    Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
    Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis.
    Kirbas A; Kirbas S; Anlar O; Efe H; Yilmaz A
    J Clin Neurosci; 2013 Aug; 20(8):1106-9. PubMed ID: 23669169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.
    Krumbholz M; Pellkofer H; Gold R; Hoffmann LA; Hohlfeld R; Kümpfel T
    Arch Neurol; 2007 Sep; 64(9):1331-3. PubMed ID: 17846274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis.
    Escribano BM; Aguilar-Luque M; Bahamonde C; Conde C; Lillo R; Sanchez-Lopez F; Giraldo AI; Cruz AH; Luque E; Gascon F; Aguera E; Tunez I
    Curr Pharm Des; 2016; 22(31):4876-4880. PubMed ID: 27396595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N; Tambour M; Henriksson F; Fredrikson S
    J Med Econ; 2013; 16(3):349-57. PubMed ID: 23211038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.